
- /
- Supported exchanges
- / US
- / OCUL.NASDAQ
Ocular Therapeutix Inc (OCUL NASDAQ) stock market data APIs
Ocular Therapeutix Inc Financial Data Overview
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ocular Therapeutix Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ocular Therapeutix Inc data using free add-ons & libraries
Get Ocular Therapeutix Inc Fundamental Data
Ocular Therapeutix Inc Fundamental data includes:
- Net Revenue: 56 664 K
- EBITDA: -237 316 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ocular Therapeutix Inc News

H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best healthcare stocks with the highest upside. Ocular Therapeutix Inc. (NASDAQ:OCUL) received a rating update from H.C. Wainwright on October 8. Th...


Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks with high potential. On October 3, Piper Sandler raised the firm’s price target on Ocular Therapeutix Inc. (NASDAQ:OCUL) to $3...

Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale
We recently published 11 Stocks Failing to Keep up With The Market. Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the top performers on Tuesday. Ocular Therapeutix saw its share prices drop by 6.7 ...

Wednesday's ETF with Unusual Volume: XPH
The SPDR S&P Pharmaceuticals ETF is seeing unusually high volume in afternoon trading Wednesday, with over 194,000 shares traded versus three month average volume of about 30,000. Shares of XPH were ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.